Merck (MRK) Announces License Agreement with The Medicines Patent Pool for Molnipiravir

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LEN
8. USO
9. LMT
10. TLT

Go back to Merck (MRK) Announces License Agreement with The Medicines Patent Pool for Molnipiravir

The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countri

October 27, 2021 6:00 AM EDT

Merck, Ridgeback Biotherapeutics and Emory University Will Not Receive Royalties for Sales of Molnupiravir Under this Agreement for as Long as COVID-19 Remains Classified as a Public Health Emergency of International Concern by the World Health Organization

Collaboration Continues Mercks Long Track Record of Making Its Medicines and Vaccines Accessible and Affordable Globally

This is the First MPP Agreement to Provide Access for a COVID-19 Medical Technology

KENILWORTH, N.J.--(BUSINESS WIRE)-- The Medicines Patent Pool (MPP) and Merck (NYSE:... More